Lung cancer trial aims to zap tumors harder
NCT ID NCT02788461
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This trial tests whether giving a higher radiation dose to the most active parts of a lung tumor can better control the cancer. About 78 people with locally advanced non-small cell lung cancer will receive either standard chemoradiation or chemoradiation with an extra radiation boost. The study will compare how well each approach prevents the cancer from coming back in the chest over two years.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Radiation therapy with or without a boost dose
- What this could lead to
- If successful, this approach could reduce the chance of lung cancer returning in the chest after standard chemoradiation.
- What could go wrong
- This is a small, early-phase trial with only 78 participants, so results may not apply to all patients. Higher radiation doses also carry a risk of increased side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 78 people
The number the study aims to enrol. It can still change while the study runs.
- Start date
-
May 2016
- Expected to finish
-
Apr 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients who are at least 18 years old and are able to consent * Patients who will undergo Chemo-RT as primarily modality of treatment * Patients with a primary tumor or node measuring at least 10mm on CT scan * Patients with a PET avid tumor having Standardized Uptake Values (SUV) \> 4 * Patients with Eastern Cooperative Oncology Group (ECOG) status 0-2 within 4 weeks of randomization Exclusion Criteria: * Trimodality patients who have surgery as part of curative treatment * Previous radiotherapy to intended treatment volumes * Active invasive malignancy other than lung cancer * Active pregnancy * Poor respiratory function (Forced Expiratory Volume \< 1.0 or Diffusing Capacity \< 50% age-adjusted normal) * ECOG status \> 2 * Pre-treatment complete blood count/differential showing inadequate bone marrow reserve (absolute neutrophil count \< 1800 cells/mm3 or platelets \< 100 000 cells/mm3 or hemoglobin \< 90g/L), measured within 4 weeks of registration * AST, ALT or total bilirubin \> 2.5 times the upper limit of normal, measured within 4 weeks of registration * Unintentional weight loss \>10% over 3 months within 4 weeks of registration * Severe active co-morbidity defined by: * Significant history of uncontrolled cardiac disease; i.e. uncontrolled hypertension, unstable angina, myocardial infarction within the last 6 months, uncontrolled congestive heart failure, cardiomyopathy with decreased ejection fraction * Transmural myocardial infection requiring intravenous antibiotics at the time of registration * Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days before randomization * Acquired immune deficiency syndrome (AIDS) based on the current Centre for Disease Control definition; note, however, that HIV testing is not required for entry into this protocol
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Quebec - L'Hôtel-Dieu de Québec
Québec, Quebec, G2L 2Z3, Canada
-
CHUS - Hôpital Fleurimont
Sherbrooke, Quebec, J1H 5N4, Canada
-
Kingston General Hospital
Kingston, Ontario, K7L 2V7, Canada
-
London Regional Cancer Program
London, Ontario, N6A 4L6, Canada
-
McGill University Health Centre, Glen site Cedars Cancer Center
Montreal, Quebec, H4A 3J1, Canada
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
-
Stronach Regional Cancer Centre at Southlake Regional Health Centre
Newmarket, Ontario, L3Y 2P9, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Surgeons could freeze lung tumors from miles away using 5G robots
- Two-Drug combo targets stubborn KRAS lung cancer
- Smaller chest drain may speed recovery after lung cancer surgery
- Gut bacteria may hold clues to why some cancer treatments work better
- Breath-Tracking sensor aims to sharpen lung cancer scans
- Can PET scan signals predict who beats lung cancer with immunotherapy?